MDT

95.61

+0.82%↑

VEEV

300.34

+2.34%↑

A

138.64

-0.03%↓

HQY

89.66

-1.24%↓

PHR.US

22.83

+1.69%↑

MDT

95.61

+0.82%↑

VEEV

300.34

+2.34%↑

A

138.64

-0.03%↓

HQY

89.66

-1.24%↓

PHR.US

22.83

+1.69%↑

MDT

95.61

+0.82%↑

VEEV

300.34

+2.34%↑

A

138.64

-0.03%↓

HQY

89.66

-1.24%↓

PHR.US

22.83

+1.69%↑

MDT

95.61

+0.82%↑

VEEV

300.34

+2.34%↑

A

138.64

-0.03%↓

HQY

89.66

-1.24%↓

PHR.US

22.83

+1.69%↑

MDT

95.61

+0.82%↑

VEEV

300.34

+2.34%↑

A

138.64

-0.03%↓

HQY

89.66

-1.24%↓

PHR.US

22.83

+1.69%↑

Search

Kymera Therapeutics Inc

Suletud

SektorTervishoid

55.69 1.96

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

54.11

Max

55.97

Põhinäitajad

By Trading Economics

Sissetulek

-11M

-77M

Müük

-11M

11M

Aktsiakasum

-0.95

Kasumimarginaal

-667.602

Töötajad

218

EBITDA

-21M

-85M

Soovitused

By TipRanks

Soovitused

Tugev "osta" hinnang

12 kuu keskmine prognoos

+17.33% upside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

31. okt 2025

Turustatistika

By TradingEconomics

Turukapital

1.5B

4.2B

Eelmine avamishind

53.73

Eelmine sulgemishind

55.69

Uudiste sentiment

By Acuity

50%

50%

149 / 371 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Weak Bullish Evidence

Kymera Therapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

1. nov 2024, 03:00 UTC

Peamised uudised

U.S. Drugmakers Are Breaking Up With Their Chinese Supply-Chain Partners -- WSJ

Võrdlus sarnastega

Hinnamuutus

Kymera Therapeutics Inc Prognoos

Hinnasiht

By TipRanks

17.33% tõus

12 kuu keskmine prognoos

Keskmine 64.13 USD  17.33%

Kõrge 88 USD

Madal 53 USD

Põhineb 17 Wall Streeti analüütiku instrumendi Kymera Therapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

17 ratings

17

Osta

0

Hoia

0

Müü

Tehniline skoor

By Trading Central

28.34 / 33.56Toetus ja vastupanu

Lühikene perspektiiv

Weak Bullish Evidence

Keskpikk perspektiiv

Bullish Evidence

Pikk perspektiiv

Weak Bearish Evidence

Sentiment

By Acuity

149 / 371 Pingereas Tervishoid

Uudiste sentiment

Neutral

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Kymera Therapeutics Inc

Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
help-icon Live chat